Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Czechia / NCT06629701
Enrolling by invitation Not applicable

A Prospective Randomized Trial of External Vein Graft Support in Surgical Myocardial Revascularization

NCT06629701 · tracked via the Priya Life Science Czechia tracker
Sponsor
University Hospital Pilsen
Phase
Not applicable
Started
2024-01-01
Last updated
2026-04-09

Condition(s) studied

Heart Attack, Revascularization

Investigational drug(s) / intervention(s)

External support for vein grafts

External support for vein grafts: Group A will consist of a group of patients who will be sutured with external support for vein grafts.

Study summary

The aim of the thesis is to compare a group of patients using vein grafts with and without external support, specifically their patency. This is a prospective study with a follow-up plan of 150 patients, in whom the functionality of the grafts will be monitored at time intervals.

Eligibility

Sex
ALL
Min age
20 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria: * elective cardiosurgical revascularization using VSM vein graft, i.e. patients with MVD findings. Exclusion Criteria: * thromboembolic event in the past, long-term warfarinization, mechanical valves, infection during the procedure, urgent procedure, allergy to contrast material, pregnancy, elevated creatinine. A relative contraindication for exclusion from the study is: VSM varicosity, VSM damage during sampling.The age, gender or weight of the patient has no influence on the indication.

Primary outcome measure(s)

  • Closing of bypass in time — 3 years after the operation
    Primary measures will be closing of the bypass in time, if there will be any.

Trial sites (1)

FacilityCityRegionStatus
University Hospital Pilsen Pilsen Czech Republic

More University Hospital Pilsen trials in Czechia

Quantification of Peripheral Blood iNKTs After Allogeneic Stem Cell Transplantation Recruiting
Transorbital Ultrasound and Other Markers for Prognosis Prediction After Cardiac Arrest Active, not recruiting
Comparison of Skin Prick Testing, Extract-specific IgE Antibody Testing and Component Resolved Diagnosis in Diagnosing of Legume Allergy Recruiting
Study SOLACE SEPSIS Recruiting
Cannabis Abstinence and Neurocognitive Assessment in Adolescence Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06629701 on ClinicalTrials.gov ↗ ← All trials in Czechia